Overview

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Status:
Active, not recruiting

Trial end date:
2022-03-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate, in patients with tumors known to express the protein mesothelin, the following properties of BAY2287411 injection: - safety (to identify, assess, minimize, and appropriately manage the risks associated to the study drug) - tolerability (the degree to which side effects can be tolerated by your body) - maximum tolerated dose - pharmacokinetics (the effect of your body on the study drug) - anti-tumor activity - recommended dose for further clinical development

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Antibodies
BAY 2287411
Chelating Agents
Immunoglobulins